Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See
full details
.
I Agree
×
Join today and have your say! It’s FREE!
Join Now
Sign In
Become a member today, It's free!
We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.
Join Today
or
Sign in with existing account
Privacy Policy
|
Disclaimer
Sign In
Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Remember me
Forgot Password?
Sign In
or
Sign Up
Privacy Policy
|
Disclaimer
Please Try Again
{{ error }}
Send my password
Submit
Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.
Become a member today, It's free!
We will not release or resell your information to third parties without your permission.
Linking with Facebook:
Stockhouse membership requires an email address which must be shared by Facebook.
By default, joining or signing in using your Facebook account will work and the email address will be shared by Facebook automatically.
If you change your Facebook permissions to restrict Stockhouse from receiving your email while joining or signing in to Stockhouse then it will fail.
Please do not modify the permission settings during sign-in.
Sign in with Facebook
Return to Signup Options
Home
Community
Bullboards
Blogs
Groups
Messages
Markets
Stocks
TSX
TSXV
CSE
Cboe Canada
NASDAQ
NYSE
NYSE American
Cryptocurrency
Currencies
Market Movers
Bonds
News
Featured News
Trending News
Canadian Press Releases
US Press Releases
Video
Editorial
Thematic Insights
Independent Reports
Interviews
Buzz on the Bullboards
Portfolio
Watchlist
Portfolio
Showcase Companies
DealRoom
Quote
|
Bullboard
|
News
|
Opinion
|
Profile
|
Peers
|
Filings
|
Financials
|
Options
|
Price History
|
Ratios
|
Ownership
|
Insiders
|
Valuation
Bullboard - Stock Discussion Forum
Reunion Neuroscience Inc
T.REUN
Healthcare
Biotechnology
Reunion Neuroscience Inc. is engaged in the psychedelic drug development company that provides therapeutic solutions for mental health conditions by developing serotonin receptor agonist compounds. The Company is developing the advancement of synthetic molecules targeting serotonin 5HT2A receptors. The Company’s products include RE104 and RE200. The Company’s lead asset, RE-104, which is a...
psychedelic drug being developed for post-partum and treatment resistant depression as a potential fast-acting antidepressant with durable efficacy. The RE104 as a potentially fast-acting treatment for the key indications of postpartum and treatment resistant depression. The Company is developing the RE200 series, which includes compounds with potential for more selective serotonin receptor activity with reduced psych activity for potential use in more chronic treatment paradigms and indications. The Company is focused on the research and development of its RE200 molecule group.
see more
Join the community and start posting on the bullboards today. It's free.
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
Create a portfolio watchlist today. It's free.
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
Add To Watchlist
Bullboard (TSX:REUN)
New Post
View:
Posts & Comments
Threaded Posts
Prev
1
2
3
4
5
Next
(45)
•••
Idvhmz123
X
View Profile
View Bullboard History
Post by
Idvhmz123
on May 11, 2021 9:01am
Psychedelic News
ORIGINAL: Havn Life Develops New Method for Rapid Psilocybin Testing 2021-05-11 08:03 ET - News Release Havn Life has completed its analytical work under its Health Canada Section 56 exemption
...more
(0)
•••
rednip
X
View Profile
View Bullboard History
Post by
rednip
on May 09, 2021 8:49pm
Some may find this article of interest
https://www.nytimes.com/2021/05/09/health/psychedelics-mdma-psilocybin-molly-mental-health.html
(36)
•••
BryceCanada
X
View Profile
View Bullboard History
Post by
BryceCanada
on May 01, 2021 10:35am
Excellent YT analysis on TRIP, GLTA!
https://youtu.be/k_2jeRmHL0I
(36)
•••
BryceCanada
X
View Profile
View Bullboard History
Post by
BryceCanada
on May 01, 2021 10:22am
Great watch for FTRP longs!
https://youtu.be/47XFv8AkGNs
(36)
•••
BryceCanada
X
View Profile
View Bullboard History
Post by
BryceCanada
on Apr 24, 2021 9:08am
Deep dive on FTRP
https://youtu.be/47XFv8AkGNs
(36)
•••
BryceCanada
X
View Profile
View Bullboard History
Post by
BryceCanada
on Apr 17, 2021 11:44am
Excellent FTRP YT Analysis
https://youtu.be/47XFv8AkGNs
(36)
•••
BryceCanada
X
View Profile
View Bullboard History
Post by
BryceCanada
on Apr 10, 2021 11:54am
Excellent YT analysis
https://youtu.be/47XFv8AkGNs
(36)
•••
BryceCanada
X
View Profile
View Bullboard History
Post by
BryceCanada
on Apr 05, 2021 4:32pm
Great YT Analysis on FTRP!
https://youtu.be/47XFv8AkGNs
(0)
•••
Bigguy
X
View Profile
View Bullboard History
Post by
Bigguy
on Mar 25, 2021 11:48am
Mushrooms for everyone!
https://www.thegrowthop.com/life/chelsea-handler-takes-mushrooms-before-appearance-on-the-tonight-show-with-jimmy-fallon
(44)
•••
evilballs
X
View Profile
View Bullboard History
Post by
evilballs
on Feb 28, 2021 7:49pm
$82M Bought Deal
Seems like I chose correct. This stock is going top go up in valuation simialr to Mind Med or Compass.
(44)
•••
evilballs
X
View Profile
View Bullboard History
Post by
evilballs
on Feb 22, 2021 10:48pm
$8 level seems to have been attained
I have a firm beleif this is a billion dollar company this year. The only area where they are receiving any type of poor marks is their app. A minimum 20 treatment centers within the year
...more
(44)
•••
evilballs
X
View Profile
View Bullboard History
Post by
evilballs
on Feb 16, 2021 11:21pm
MD & A says it all...
20 to 30 clinics opend up by this time next year. I have heard average revenue once fully operational in excess of $1M per year Also have synthetic psilocybin that lasts half the duration
...more
(44)
•••
evilballs
X
View Profile
View Bullboard History
Post by
evilballs
on Feb 12, 2021 2:38am
Some coverage
Beat the Market Stock Picks | Seeking market alpha with undervalued high growth opportunities… Hopefully Field Trip Health isn't a small cap one day.
(44)
•••
evilballs
X
View Profile
View Bullboard History
Post by
evilballs
on Feb 12, 2021 2:25am
Niche in the portfolio
When it comes to this subsector there was not a lot to chose from who distinguished themselves in this category I think NovaMind was the other company. The fact they have an international
...more
(44)
•••
evilballs
X
View Profile
View Bullboard History
Comment by
evilballs
on Feb 12, 2021 2:03am
RE:RE:Fieldtrip
The warrants. Someone needs to buy the warrants. I know they haven't been listed long but geez... stock closes at $2.40 in the money but the warrants close at $1.80... Should be
...more
Prev
1
2
3
4
5
Next
Thank You
Your Report has been submitted.
Report Abusive Content
×
Close
Sign up to get access
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
The Market Update
{{currentVideo.title}}
{{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >
A daily snapshot of everything
from market open to close.
{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}
{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >
Featured News Links
This $10M Deal Could Reshape the Future of Global Creator Platforms
New Gold and Copper Hotspot Identified – What’s Next for This Serbian Project?
Major Funding Secured! Company Closes First Round of Private Placement